Surgery

A machine learning model incorporating treated astigmatism and nuanced inputs is advancing the precision and personalization of arcuate keratotomy planning

Discover how real-world evidence shapes cataract surgery practices, highlighting user satisfaction with enhanced monofocal IOLs at the 2025 ASCRS Annual Meeting.

Discover how dropless cataract surgery enhances patient comfort and outcomes, reducing the need for eye drops and improving recovery efficiency.

Pykus Therapeutics reveals promising results for PYK-2101, a retinal sealant that enhances recovery and improves patient experience in retinal detachment surgery.

Alex Hacopian, MD, highlights how a recent ambispective study demonstrated strong visual acuity outcomes and patient satisfaction following bilateral implantation of an advanced presbyopia-correcting intraocular lens.

George O. Waring IV, MD, FACS, discusses the “vision for a lifetime” approach and how modern advancements allow tailored treatments for every stage of eye maturity.

This population requires careful attention from diagnosis through the entire postoperative process.

Five years after the COVID-19 pandemic shutdown reshaped how the world gathers, here's how some of ophthalmology’s leading associations are still applying lessons forged in crisis

Mah previews a packed 2025 Annual Meeting, from the debut of SightLine to Dr. Glaucomflecken’s return to the main stage, and outlines his priorities for the year ahead as incoming ASCRS president.

Personalizing treatment options and setting realistic expectations are crucial.

The May 4 event, themed around Star Wars, will feature the latest innovations, foster open discussions, and provide a collaborative environment for networking and learning, with sessions covering IOLs, oculoplastics, glaucoma, retina therapy, and refractive surgical options.

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss.

Vision correction has evolved into a continuum of procedures suited for different stages of ocular maturity

A combination of canaloplasty and goniotomy provides sustained IOP reduction and decreases medication burden with a strong safety profile, making it a valuable option for glaucoma management.

The recent agreement with Cipla adds to the list of partnerships Formosa has formed for APP13007.

These offerings are designed to streamline workflows for eye care professionals and enhance patient experience.

This preservative-free synthetic corticosteroid is approved by the FDA for visualization during vitrectomy and the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.

The research analyzed the 1-year outcomes of 132 eyes, evaluating mean IOP, baseline changes, medication reduction, and stratifying the results by race (African American vs Caucasian) and glaucoma severity (mild, moderate, severe).

The procedure offers a renewed approach to suprachoroidal drainage, with potential for both combined and standalone glaucoma surgery.

The Elios procedure increased aqueous humor outflow in all investigated eyes, but further studies are needed to correlate these improvements with its clinical efficacy.

Monofocal IOLs, along with advanced phacoemulsification technology, offer tailored solutions.

Shameema Sikder, MD; and T. Y. Alvin Liu, MD, highlight the technology’s role in bridging challenges and successes for clinical practice.

The state-of-the-art facility more than doubles the institute’s footprint, enhancing patient care, research, and education.

Direct selective laser trabeculoplasty enhances the experience for both patients and physicians, he notes, while also mitigating issues related to poor adherence and ocular surface disease from topical therapy.

The new first-line laser treatment for glaucoma and ocular hypertension will be unveiled at the 2025 American Glaucoma Society annual meeting in Washington, DC, from February 26 to March 2.

The focus in recent years has shifted to reducing the long-term burden of medical therapy, minimizing the risk of medication toxicity and persistent ocular surface disease.

The company plans on launching VIA360 immediately in the US market.

Ooms' poster at the Association of University Professors of Ophthalmology annual meeting highlighted a study on gray area complications in strabismus surgery, showing that trainees are more likely than attendings to disclose these complications despite having similar baseline anxiety levels. Ooms is a PGY-4 ophthalmology resident at the Dean McGee Eye Institute.

The pandemic caused an overall decrease in the rates of the 10 most common ophthalmic procedures performed in 2020 when compared to the year prior.